Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.
RetiCare IVS – Setting the sight on new treatments for retinal diseases
RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.
The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.
Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.
The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Profile
DataHow AG is a spin-off company from ETH Zurich specialized in data analytics and process modeling for the process industry with a particular focus on the production of biopharmaceuticals.
We offer digital solutions and consulting for process screening, monitoring, optimization, control and scale-up. Our goal is to reduce the effort, risks and costs in process development and manufacturing as well as to gain deep understanding of the complex processes.
DataHow emerged in 2017 from the research group of Prof. Morbidelli at ETH Zurich based on the activities of Dr. Alessandro Butté, Michael Sokolov and Fabian Feidl.
TOLREMO is an ETH Spin-off founded in March 2017. The company engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. Despite medical advances, resistance to cancer therapies continues to limit the long-term survival of many cancer patients. The company’s innovative therapeutic approach specifically eradicates those cancer cells that ultimately cause drug resistance. Its science-based drug discovery and development pipeline is fueled by a unique screening platform for which a patent has been filed. TOLREMO’s vision is to use its personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.
Responsive Web Design powered by 